| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Cartesian Therapeutics, Inc. (RNAC) has 13 insiders with recent SEC Form 4 filings, including 3 buys and 9 sells. RNAC is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 8.65M | $72.80M | - | |
| 10% | 511.6K | $4.31M | - | |
| CEO | 323.5K | $2.72M | - | |
| CFO | 121.2K | $1.02M | - | |
| Other | 94.2K | $793.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2017 | Siewers David | Chief Financial Officer | Sell | 6,886 | $20.00 | $137,720.00 | -99.5% | |
| Jun 15, 2017 | Johnston Lloyd P.74 | COO And SVP, R*d | Sale+OE | 20,512 | $17.00 | $348,640.41 | -92.7% | |
| Jun 1, 2017 | Springer Timothy A49 | Director | Buy | 518 | $13.75 | $7,122.50 | +3.2% | |
| May 18, 2017 | Springer Timothy A49 | Director | Buy | 16,104 | $14.00 | $225,523.46 | +143.2% | |
| May 16, 2017 | Kania Edwin M Jr | Director | Sell | 266,795 | $14.00 | $3,735,130.00 | -32.3% | |
| Apr 17, 2017 | Johnston Lloyd P.74 | COO And SVP, R&D | Sale+OE | 13,205 | $13.95 | $184,209.75 | -89.2% | |
| Jan 23, 2017 | Johnston Lloyd P.74 | COO And SVP, R&D | Sale+OE | 15,000 | $14.01 | $210,105.80 | -67.9% | |
| Dec 28, 2016 | Kishimoto Takashi Kei73 | Chief Scientific Officer | Sale+OE | 10,000 | $17.55 | $175,500.00 | -100% | |
| Dec 21, 2016 | Abraham David | CCO, Gen.counsel, Corp.sec. | Sale+OE | 14,844 | $18.00 | $267,192.00 | -100% | |
| Dec 19, 2016 | Keller Peter | Chief Business Officer | Sell | 4,723 | $18.58 | $87,753.34 | -92.1% |